Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells

Citation
E. Ackerstaff et al., Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells, CANCER RES, 61(9), 2001, pp. 3599-3603
Citations number
40
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER RESEARCH
ISSN journal
0008-5472 → ACNP
Volume
61
Issue
9
Year of publication
2001
Pages
3599 - 3603
Database
ISI
SICI code
0008-5472(20010501)61:9<3599:DOICCW>2.0.ZU;2-C
Abstract
In this study, a panel of normal human prostate cells (HPCs) and tumor cell s derived from metastases were studied hy H-1 NMR spectroscopy to determine whether the malignant transformation of HPCs results in the elevation of c holine compounds. Although an elevated choline signal has been observed pre viously in clinical studies, the contribution of the different Cho compound s to this elevation, as well as their quantification, has not been establis hed until now. Here wt! have shown that HPCs derived from metastases exhibi t significantly higher phosphocholine as well as glycerophosphocholine leve ls compared with normal prostate epithelial and stromal cells. Thus the ele vation of the choline peak observed clinically in prostate cancer is attrib utable to an alteration of phospholipid metabolism and not simply to Increa sed cell density, doubling time, or other nonspecific effects, Androgen dep rivation of the androgen receptor-positive cell lines resulted in a signifi cant increase of choline compounds after chronic androgen deprivation of th e LNCaP cell line and in a decrease of choline compounds after a more acute androgen deprivation of the LAPC-4 cell line. These data strongly support the use of proton magnetic resonance spectroscopic imaging to detect the pr esence of prostate cancer for diagnosis, to detect response subsequent to a ndrogen ablation therapy, and to detect recurrence.